Navigation Links
Biodel Announces Name Change for Lead Product Candidate
Date:9/1/2010

DANBURY, Conn., Sept. 1 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's  most advanced product candidate.  The change follows FDA's review and acceptance of Linjeta™ as an alternative name for Biodel's more-rapid-acting insulin formulation that is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Application date of October 30, 2010.  

Dr. Errol De Souza, Biodel 's president and chief executive officer, stated: "Today's news reflects the continued progress of the Linjeta™ new drug application through FDA review and is an important milestone in our effort to commercialize this new drug candidate."

About Biodel Inc. Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.  Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new drug application for Linjeta™, its most advanced product candidate, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010.  Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon.  For further information regarding Biodel, please visit the company's website at www.biodel.com. Contact:The Trout Group LLCSeth D. Lewis, +1-646-378-2952
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey ... of LabKey’s newest software solution, LabKey Biologics . Built in collaboration with ... biotech organizations, LabKey Biologics provides drug research teams tools for biological entity registration, ...
(Date:3/28/2017)... 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ... safety and clinical data from its phase 1/2 tendon repair ... follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The ... profile at 6 months and showed no serious adverse events ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... to accelerating the fight against cancer, autoimmune disease and more through a single-cell ... single-cell metabolomics and proteomics analysis platform developed in the laboratory of Dr. ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
Breaking Biology News(10 mins):